etf1 min
Alteogen因Halozyme核心专利被判无效股价上涨4%
发布: · 来源: mk.co.kr
一句$话总结: Alteogen在竞争对手Halozyme核心专利被判无效后，被认为在皮下注射制剂技术专利纠纷中取得有利位置，股价上涨约4%。
广告
11개 언어 자동 번역
Alteogen股价在竞争对手Halozyme核心专利被判无效的消息传出后上涨约4%。两家公司目前正围绕皮下注射（SC）制剂技术进行专利纠纷，此次判断被解读为Alteogen在争议中取得了更有利的位置。原文还提到，KOSDAQ和风险企业协会呼吁优质企业继续留在KOSDAQ市场。市场认为，专利纠纷的进展正在直接影响Alteogen的股价和投资者情绪。来源: mk.co.kr
广告
매일 5분 안에 핵심 뉴스
Partner picks
Relevant partner links for this story
A lightweight commerce block designed to add monetization without breaking reading flow.
Coupang PartnersKR conversion
Good fit for Korea-based visitors ready to buy.
View offerAliExpressBudget picks
Works well for price-sensitive gadget and desk-tool traffic.
View offerAmazon AssociatesGlobal reach
Useful for books, work tools, and international shoppers.
View offerThis module may include affiliate links that earn a commission from qualifying purchases. ETF와이어
Sponsored
11개 언어 자동 번역
한 번 작성하면 11개 언어로 자동 노출
广告
매일 5분 안에 핵심 뉴스
